Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine

Gene Therapy

Volumn 6, Issue 5, 1999, Pages 865-872

  Rodolfo, M ^a   Zilocchi, C ^a   Cappetti, B ^a   Parmiani, G ^a   Melani, C ^a   Colombo, M P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

CTL; Cytokine gene transfer; Tumor immunity

Indexed keywords

INTERLEUKIN 12; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CELL MEDIATED CYTOTOXICITY; CLONING VECTOR; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; LONG TERMINAL REPEAT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLEEN LYMPHOCYTE; SPLENECTOMY; TUMOR IMMUNITY;

ADENOCARCINOMA; ANIMALS; CANCER VACCINES; COLONIC NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENE EXPRESSION; GENE THERAPY; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; TRANSFECTION;

ANIMALIA;

EID: 0032980885     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300874     Document Type: Article

References (39)

1. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997; 18: 267-268.
2. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18: 175-185.
3. Mitchell MS. Active specific immunotherapy of melanoma. Br Med Bull 1995; 51: 631-646.
4. Morton DL et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-482.
5. Parmiani G, Colombo MP, Melani C, Arienti F. Cytokine gene transduction in the immunotherapy of cancer. Adv Pharmacol 1997; 40: 259-308.
6. Musiani P et al. Cytokines, tumor-cell death and immunogenicity: a question of choice. Immunol Today 1997; 18: 32-36.
7. + cytotoxic-T cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996; 66: 470-476.
8. Lehmann M et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25: 343-347.
9. Cormier JN et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998; 75: 517-524.
10. Huang AS et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 1996; 93: 9730-9735.
11. Rodolfo M et al. Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T cell receptors. Int J Cancer 1994; 57: 440-447.
12. Coney LR et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991; 51: 6125-6132.
13. Mantovani LT et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer 1994; 30: 363-369.
14. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptative immunity. Annu Rev Immunol 1995; 13: 251-276.
15. Rodolfo M et al. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol 1996; 157: 5536-5542.
16. Salgaller ML. Monitoring of cancer patients undergoing active or passive immunotherapy. J Immunother 1997; 20: 1-14.
17. Arienti F et al. Limited antitumor T cell response in melanoma patients vaccinated with IL-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1996; 7: 1955-1963.
18. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56: 4749-4757.
19. Cormier JN et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sc Am 1997; 3: 37-44.
20. Saito S et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 1994; 54: 3516-3520.
21. Brichard V et al. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Eur J Immunol 1995; 25: 664-671.
22. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996; 8: 831-836.
23. Van Waes C et al. Immunodominance deters the response to other tumor antigens thereby favouring escape: prevention by vaccination with tumor variants selected with cloned cytolytic cells in vitro. Tissue Antigens 1996; 47: 399-407.
24. Maeurer MJ et al. Tumor escape from immune recognition; lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996; 98: 1633-1641.
25. + T cells to an antigen that no longer serves as a target. J Exp Med 1993; 178: 933-940.
26. Weber M et al. Expression of the Mage-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res 1994; 54: 1766-1771.
27. De Smet M et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 1996; 93: 7149-7153.
28. Habers K et al. DNA methylation and gene expression: endogenous retroviral genome becomes infectious after molecular cloning. Proc Natl Acad Sci USA 1981; 78: 7609-7613.
29. Tahara H et al. Effective eradication of established murine tumors with IL-12 therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-6474.
30. Hock H et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor α, or Interferon γ. Proc Natl Acad Sci USA 1993; 90: 2774-2778.
31. Goedegebuure PS et al. Reactivity of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg Oncol 1994; 3: 79-85.
32. Schwartzentruber DJ et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994; 12: 1475-1508.
33. Chang AE et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997; 15: 796-807.
34. Grabstein KH et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986; 232: 506-508.
35. Thomassen MJ et al. Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy. Cancer Res 1991; 51: 857-862.
36. + T cells and GM-CSF. J Exp Med 1998; 188: 133-143.
37. Eberl G et al. Immunodominance of cytotoxic T lymphocyte epitopes coinjected in vivo and modulation by interleukin-12. Eur J Immunol 1996; 26: 2709-2716.
38. Miotti S et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987; 39: 297-303.
39. Langhorne J. Limiting dilution analysis of precursors of cytotoxic T lymphocytes. In: Lefkovits I, Pernis B (eds). Immunological Methods. Vol 2. Academic Press: New York, 1981, pp 221-231.